pure encapsulation liposomal glutathione Liquid by Encapsulations Liposomal Glutathione - 30 CT

When looking at the percentage of participants that dropped out of the trial due to adverse effects, 2-6% of patients in the cagrilintide group discontinued treatment early while 7% of the participants receiving liraglutide discontinued treatment early, These findings were in comparison to only 3% of test subjects from the placebo group that discontinued treatment due to adverse events [1]

doi: 10.3389/fpls.2016.01299

[4] Ultimately, the choice of GLP-1 agonist should be a collaborative decision between the patient and their healthcare provider, taking into account individual factors, treatment goals, and potential risks and benefits

Hestad K, Alexander J, Rootwelt H, Aaseth JO